Redmile Group’s Pacira BioSciences PCRX Stock Holding History

Redmile Group’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-5,190	Closed	-$237K	–	71
2017 Q4	$237K	Buy	+5,190	New	+$206K	0.01%	66

Other funds holding PCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Redmile Group's PCRX Position: Q1 2018 in Review

Redmile Group sold out of Pacira BioSciences (PCRX) in Q1 2018, closing a stake of 5,190 shares — an estimated $237K sold.

Redmile Group first reported a position in PCRX in Q4 2017 and held it in 1 quarter. The position peaked at $237K in Q4 2017. 168 funds tracked by Wall St. Rank hold PCRX as of Q1 2018.

Redmile Group reported no remaining Pacira BioSciences position as of Q1 2018 after selling out during the quarter.
Redmile Group sold 5,190 Pacira BioSciences shares in Q1 2018, an estimated $237K.
Redmile Group first reported a position in Pacira BioSciences in Q4 2017 and held it in 1 quarter.
Redmile Group's Pacira BioSciences position peaked at $237K in Q4 2017.
168 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2018.

Based on Redmile Group's 13F filing for Q1 2018, filed 15 May 2018.